Chronic Pain - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 320 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chronic Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chronic Pain - Pipeline Review, H2 2014', provides an overview of the Chronic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Chronic Pain Overview 11
Therapeutics Development 12
Pipeline Products for Chronic Pain - Overview 12
Pipeline Products for Chronic Pain - Comparative Analysis 13
Chronic Pain - Therapeutics under Development by Companies 14
Chronic Pain - Therapeutics under Investigation by Universities/Institutes 20
Chronic Pain - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Chronic Pain - Products under Development by Companies 26
Chronic Pain - Products under Investigation by Universities/Institutes 34
Chronic Pain - Companies Involved in Therapeutics Development 35
DURECT Corporation 35
Johnson & Johnson 36
Allergan, Inc. 37
UMeWorld Limited 38
AstraZeneca PLC 39
Eli Lilly and Company 40
Nektar Therapeutics 41
Daiichi Sankyo Company, Limited 42
Merck & Co., Inc. 43
Santen Pharmaceutical Co., Ltd. 44
Egalet Corporation 45
Daewoong Pharmaceutical Co., Ltd. 46
Laboratorios Del Dr. Esteve S.A. 47
Glenmark Pharmaceuticals Ltd. 48
Nippon Shinyaku Co., Ltd. 49
Orion Corporation 50
Pain Therapeutics, Inc. 51
Pfizer Inc. 52
Purdue Pharma L.P. 53
Teva Pharmaceutical Industries Limited 54
Collegium Pharmaceutical, Inc. 55
Bionomics Limited 56
Acadia Pharmaceuticals Inc. 57
Pozen, Inc. 58
Mertiva AB 59
INSYS Therapeutics, Inc. 60
Chromocell Corporation 61
BCN Peptides, S.A. 62
Phosphagenics Limited 63
Pharmaleads 64
Grunenthal GmbH 65
CoLucid Pharmaceuticals, Inc. 66
Trevena, Inc. 67
Syntrix Biosystems, Inc. 68
Kineta, Inc. 69
Rottapharm SpA 70
QRxPharma Limited 71
Cara Therapeutics, Inc. 72
arGEN-X BV 73
Moberg Pharma AB 74
Janssen Research & Development, LLC 75
Dompe Farmaceutici S.p.A. 76
Endo Pharmaceuticals Inc. 77
Lohocla Research Corporation 78
Relmada Therapeutics, Inc. 79
Afferent Pharmaceuticals, Inc. 80
Convergence Pharmaceuticals Ltd. 81
Adynxx, Inc. 82
Kareus Therapeutics, SA 83
Astraea Therapeutics, LLC 84
Signature Therapeutics, Inc 85
AnaBios Corporation 86
CFR Pharmaceuticals SA 87
Recro Pharma, Inc. 88
Creabilis SA 89
Neura Therapeutik, LLC 90
AbbVie Inc. 91
Nanomerics Ltd 92
ChironWells GmbH 93
Akron Molecules AG 94
GlobalAcorn 95
Chronic Pain - Therapeutics Assessment 96
Assessment by Monotherapy Products 96
Assessment by Combination Products 97
Assessment by Target 98
Assessment by Mechanism of Action 103
Assessment by Route of Administration 108
Assessment by Molecule Type 110
Drug Profiles 112
tramadol hydrochloride SR - Drug Profile 112
(oxycodone hydrochloride + naloxone hydrochloride) ER - Drug Profile 113
hydrocodone bitartrate ER - Drug Profile 115
celecoxib - Drug Profile 116
oxycodone ER - Drug Profile 118
hydrocodone bitartrate ER - Drug Profile 120
tapentadol hydrochloride - Drug Profile 122
duloxetine hydrochloride DR - Drug Profile 123
oxycodone hydrochloride ER - Drug Profile 125
buprenorphine hydrochloride - Drug Profile 126
tapentadol hydrochloride ER - Drug Profile 128
(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 131
PRC-062 - Drug Profile 133
sufentanil - Drug Profile 134
(morphine + oxycodone) CR - Drug Profile 136
AGN-XX/YY - Drug Profile 137
cebranopadol - Drug Profile 138
morphine sulfate ER - Drug Profile 140
onabotulinumtoxinA - Drug Profile 141
NKTR-181 - Drug Profile 143
dexmedetomidine hydrochloride - Drug Profile 145
mirogabalin - Drug Profile 147
levorphanol tartrate ER - Drug Profile 148
dexmedetomidine - Drug Profile 149
(celecoxib + tramadol hydrochloride) - Drug Profile 151
E-52862 - Drug Profile 153
AYX-1 - Drug Profile 154
V-116517 - Drug Profile 155
bupivacaine hydrochloride - Drug Profile 156
oxycodone - Drug Profile 158
PTI-202 - Drug Profile 160
hydromorphone - Drug Profile 162
hydrocodone bitartrate - Drug Profile 163
PL-37 - Drug Profile 164
PTI-721 - Drug Profile 165
PA-65020 - Drug Profile 166
CR-845 - Drug Profile 167
oxycodone ER - Drug Profile 169
PF-05089771 - Drug Profile 170
PF-329 - Drug Profile 172
PF-06273340 - Drug Profile 174
HS-731 - Drug Profile 175
DD-04107 - Drug Profile 176
TRV-734 - Drug Profile 177
PF-06372865 - Drug Profile 178
Small Molecule to Agonize mGlu2/3 for Chronic Pain - Drug Profile 179
DS-1971 - Drug Profile 180
AF-220 - Drug Profile 181
AF-221 - Drug Profile 182
oxymorphone - Drug Profile 183
GBR-900 - Drug Profile 184
DWJ-208 - Drug Profile 185
CT-340 - Drug Profile 186
RQ-00000008 - Drug Profile 187
CR-701 - Drug Profile 188
buprenorphine hydrochloride ER - Drug Profile 189
Z-212 - Drug Profile 190
ARX-8203 - Drug Profile 191
Small Molecule to Inhibit Cav2.2 Channel for Chronic Pain - Drug Profile 193
CNV-3000223 - Drug Profile 194
PFR-03088 - Drug Profile 195
PF-614 - Drug Profile 196
PFR-06158 - Drug Profile 197
PF-6129 - Drug Profile 198
Conjugated Stigmine Program - Drug Profile 199
Small Molecule Agonizing ER-Beta for Neurology and Pain - Drug Profile 200
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 201
Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 202
FY-101C - Drug Profile 203
Small Molecule To Inhibit GPR-84 For Chronic Pain - Drug Profile 204
grapiprant - Drug Profile 205
NE2 Endomorphin - Drug Profile 207
HS-731 - Drug Profile 208
Small Molecules to Block Nav 1.7 for Pain - Drug Profile 209
Small Molecule to Inhibit P2Y14 for Chronic Pain - Drug Profile 210
Prostatic Acid Phosphatase - Drug Profile 211
Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 212
NL-001 - Drug Profile 213
PFR-06177 - Drug Profile 214
PFR-03318 - Drug Profile 215
U-2902 - Drug Profile 216
CNV-3000164 - Drug Profile 217
A-836339 - Drug Profile 218
NL-002 - Drug Profile 219
fluticasone propionate - Drug Profile 220
CRB-0089 - Drug Profile 221
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 222
NET-END - Drug Profile 223
Drugs for Chronic Pelvic Pain - Drug Profile 224
UMB-425 - Drug Profile 225
Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 226
PFR-03321 - Drug Profile 227
Small Molecules to Inhibit TRPA1 and TRPV1 for CNS - Drug Profile 228
Omnitram - Drug Profile 230
GA-8SMOL-PAIN - Drug Profile 231
Small Molecules to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 232
SA-14867 - Drug Profile 233
TROX-1 - Drug Profile 234
BBI-11008 - Drug Profile 235
NM-0127 - Drug Profile 236
Small Molecules to Activate NOP for Pain - Drug Profile 237
buprenorphine hydrochloride - Drug Profile 238
Small Molecules to Inhibit Cav2.2 Channel for Chronic Pain - Drug Profile 239
Small Molecules to Antagonize P2X3 for Chronic Pain - Drug Profile 240
DF-2593A - Drug Profile 241
Protein to Antagonize p75NTR for Chronic Pain - Drug Profile 242
Small Molecule for Central Nervous System - Drug Profile 243
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 245
Kindolor - Drug Profile 246
CRB-0022 - Drug Profile 248
PFR-03325 - Drug Profile 249
Small Molecule To Inhibit Voltage-Gated Sodium Channel Type IX Alpha For Pain - Drug Profile 250
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 251
Small Molecules to Antagonize Tyrosine Kinase Receptor A for Chronic Pain - Drug Profile 252
Small Molecules to Inhibit NMDA Receptor and CHRNA7 for CNS - Drug Profile 253
AKR-201 - Drug Profile 254
Monoclonal Antibodies Targeting Nav1.7 for Chronic Pain - Drug Profile 255
PFR-03323 - Drug Profile 256
Small Molecule to Antagonize TRPA1 for Chronic Pain - Drug Profile 257
Peptides for Chronic Pain - Drug Profile 258
KY-1017 - Drug Profile 259
hydrocodone bitartrate ER - Drug Profile 260
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 261
GRT-6006 - Drug Profile 262
VLNX-4975 - Drug Profile 263
Monoclonal Antibodies for Chronic Pain - Drug Profile 264
Chronic Pain - Recent Pipeline Updates 265
Chronic Pain - Dormant Projects 296
Chronic Pain - Discontinued Products 302
Chronic Pain - Product Development Milestones 303
Featured News & Press Releases 303
Appendix 310
Methodology 310
Coverage 310
Secondary Research 310
Primary Research 310
Expert Panel Validation 310
Contact Us 311
Disclaimer 311

List of Tables
Number of Products under Development for Chronic Pain, H2 2014 21
Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2014 22
Number of Products under Development by Companies, H2 2014 24
Number of Products under Development by Companies, H2 2014 (Contd..1) 25
Number of Products under Development by Companies, H2 2014 (Contd..2) 26
Number of Products under Development by Companies, H2 2014 (Contd..3) 27
Number of Products under Development by Companies, H2 2014 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2014 30
Comparative Analysis by Late Stage Development, H2 2014 31
Comparative Analysis by Clinical Stage Development, H2 2014 32
Comparative Analysis by Early Stage Development, H2 2014 33
Comparative Analysis by Unknown Stage Development, H2 2014 34
Products under Development by Companies, H2 2014 35
Products under Development by Companies, H2 2014 (Contd..1) 36
Products under Development by Companies, H2 2014 (Contd..2) 37
Products under Development by Companies, H2 2014 (Contd..3) 38
Products under Development by Companies, H2 2014 (Contd..4) 39
Products under Development by Companies, H2 2014 (Contd..5) 40
Products under Development by Companies, H2 2014 (Contd..6) 41
Products under Development by Companies, H2 2014 (Contd..7) 42
Products under Investigation by Universities/Institutes, H2 2014 43
Chronic Pain - Pipeline by DURECT Corporation, H2 2014 44
Chronic Pain - Pipeline by Johnson & Johnson, H2 2014 45
Chronic Pain - Pipeline by Allergan, Inc., H2 2014 46
Chronic Pain - Pipeline by UMeWorld Limited, H2 2014 47
Chronic Pain - Pipeline by AstraZeneca PLC, H2 2014 48
Chronic Pain - Pipeline by Eli Lilly and Company, H2 2014 49
Chronic Pain - Pipeline by Nektar Therapeutics, H2 2014 50
Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 51
Chronic Pain - Pipeline by Merck & Co., Inc., H2 2014 52
Chronic Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 53
Chronic Pain - Pipeline by Egalet Corporation, H2 2014 54
Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 55
Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 56
Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 57
Chronic Pain - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 58
Chronic Pain - Pipeline by Orion Corporation, H2 2014 59
Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2014 60
Chronic Pain - Pipeline by Pfizer Inc., H2 2014 61
Chronic Pain - Pipeline by Purdue Pharma L.P., H2 2014 62
Chronic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 63
Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 64
Chronic Pain - Pipeline by Bionomics Limited, H2 2014 65
Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 66
Chronic Pain - Pipeline by Pozen, Inc., H2 2014 67
Chronic Pain - Pipeline by Mertiva AB, H2 2014 68
Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2014 69
Chronic Pain - Pipeline by Chromocell Corporation, H2 2014 70
Chronic Pain - Pipeline by BCN Peptides, S.A., H2 2014 71
Chronic Pain - Pipeline by Phosphagenics Limited , H2 2014 72
Chronic Pain - Pipeline by Pharmaleads , H2 2014 73
Chronic Pain - Pipeline by Grunenthal GmbH, H2 2014 74
Chronic Pain - Pipeline by CoLucid Pharmaceuticals, Inc., H2 2014 75
Chronic Pain - Pipeline by Trevena, Inc., H2 2014 76
Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2014 77
Chronic Pain - Pipeline by Kineta, Inc., H2 2014 78
Chronic Pain - Pipeline by Rottapharm SpA, H2 2014 79
Chronic Pain - Pipeline by QRxPharma Limited, H2 2014 80
Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 81
Chronic Pain - Pipeline by arGEN-X BV, H2 2014 82
Chronic Pain - Pipeline by Moberg Pharma AB, H2 2014 83
Chronic Pain - Pipeline by Janssen Research & Development, LLC, H2 2014 84
Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 85
Chronic Pain - Pipeline by Endo Pharmaceuticals Inc., H2 2014 86
Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2014 87
Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2014 88
Chronic Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2014 89
Chronic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 90
Chronic Pain - Pipeline by Adynxx, Inc., H2 2014 91
Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2014 92
Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2014 93
Chronic Pain - Pipeline by Signature Therapeutics, Inc, H2 2014 94
Chronic Pain - Pipeline by AnaBios Corporation, H2 2014 95
Chronic Pain - Pipeline by CFR Pharmaceuticals SA, H2 2014 96
Chronic Pain - Pipeline by Recro Pharma, Inc., H2 2014 97
Chronic Pain - Pipeline by Creabilis SA, H2 2014 98
Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2014 99
Chronic Pain - Pipeline by AbbVie Inc., H2 2014 100
Chronic Pain - Pipeline by Nanomerics Ltd, H2 2014 101
Chronic Pain - Pipeline by ChironWells GmbH, H2 2014 102
Chronic Pain - Pipeline by Akron Molecules AG, H2 2014 103
Chronic Pain - Pipeline by GlobalAcorn, H2 2014 104
Assessment by Monotherapy Products, H2 2014 105
Assessment by Combination Products, H2 2014 106
Number of Products by Stage and Target, H2 2014 109
Number of Products by Stage and Mechanism of Action, H2 2014 114
Number of Products by Stage and Route of Administration, H2 2014 118
Number of Products by Stage and Molecule Type, H2 2014 120
Chronic Pain Therapeutics - Recent Pipeline Updates, H2 2014 274
Chronic Pain - Dormant Projects, H2 2014 305
Chronic Pain - Dormant Projects (Contd..1), H2 2014 306
Chronic Pain - Dormant Projects (Contd..2), H2 2014 307
Chronic Pain - Dormant Projects (Contd..3), H2 2014 308
Chronic Pain - Dormant Projects (Contd..4), H2 2014 309
Chronic Pain - Dormant Projects (Contd..5), H2 2014 310
Chronic Pain - Discontinued Products, H2 2014 311